New study suggests statin therapy may modestly reduce disease activity and inflammation in people with systemic lupus erythematosus

A new study found statin use is associated with reduced disease activity and inflammation in people with systemic lupus erythematosus (SLE), particularly in patients younger than 40 years. People with lupus are at higher risk for heart problems, such as heart attacks and cardiovascular disease. Risk factors for heart problems include high cholesterol and high blood pressure (hypertension). High cholesterol is most commonly treated with statin drugs.

Researchers conducted a systematic literature search across multiple databases. The study included a meta-analysis, evaluating outcomes including SLE Disease Activity Index (SLEDAI), C-reactive protein (CRP), interleukin-6 (IL-6) and erythrocyte sedimentation rate (ESR). The meta-analysis identified 3,596 records, involving 12 studies. They discovered those taking statins had significantly reduced disease activity scores in controlled before–after studies (not in parallel controlled trials) and lower scores were most evident among people younger than 40 years in the parallel controlled trials analysis. Lower ESR levels and a significant reduction in IL 6 was also evident after sensitivity analysis, both of which are linked to inflammation. Statins also decreased CRP levels across study types.

Overall, the analysis found statins appear to offer benefits to people with SLE and the researchers suggest further research. Consult with your doctor before making any changes to your medication. Learn more about lupus and the heart.

Read the study